Eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria.
Hill
Anita
A
Department of Haematology, Leeds Teaching Hospitals NHS Trust.
D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D017326:Clinical Trials, Phase III as Topic; D003182:Complement C5 / Q000037:antagonists & inhibitors; D006457:Hemoglobinuria, Paroxysmal / Q000188:drug therapy*; D006801:Humans; D010865:Pilot Projects; D011237:Predictive Value of Tests; D013927:Thrombosis / Q000517:prevention & control; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D003182:Complement C5; C481642:eculizumab